Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective

Uloženo v:

Podrobná bibliografie
Vydáno v:	JAMA internal medicine Ročník 181; číslo 10; s. 1276
Hlavní autoři:	Dunn, Billy, Stein, Peter, Cavazzoni, Patrizia
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.10.2021
Témata:	Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Amyloid beta-Peptides - antagonists & inhibitors Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - economics Brain - diagnostic imaging Brain - pathology Decision Making Dose-Response Relationship, Drug Drug Approval - methods Humans Infusions, Intravenous - methods Magnetic Resonance Imaging - methods Nootropic Agents - administration & dosage Nootropic Agents - adverse effects Nootropic Agents - economics Plaque, Amyloid - diagnostic imaging Positron-Emission Tomography - methods Product Surveillance, Postmarketing Randomized Controlled Trials as Topic - methods Treatment Outcome United States United States
ISSN:	2168-6114, 2168-6114
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	2168-6114 2168-6114
DOI:	10.1001/jamainternmed.2021.4607